Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.

Adult Age of Onset Aged Anemia / chemically induced Antineoplastic Agents / adverse effects Basic Helix-Loop-Helix Transcription Factors / antagonists & inhibitors Carcinoma, Renal Cell / drug therapy Disease Progression Fatigue / chemically induced Female Follow-Up Studies Hemangioblastoma / drug therapy Humans Indenes / adverse effects Kidney Neoplasms / drug therapy Male Middle Aged Neoplasms, Multiple Primary / drug therapy Neuroendocrine Tumors / drug therapy Pancreatic Neoplasms / drug therapy von Hippel-Lindau Disease / complications

Journal

The New England journal of medicine
ISSN: 1533-4406
Titre abrégé: N Engl J Med
Pays: United States
ID NLM: 0255562

Informations de publication

Date de publication:
25 11 2021
Historique:
entrez: 24 11 2021
pubmed: 25 11 2021
medline: 15 12 2021
Statut: ppublish

Résumé

Patients with von Hippel-Lindau (VHL) disease have a high incidence of renal cell carcinoma owing to In this phase 2, open-label, single-group trial, we investigated the efficacy and safety of the HIF-2α inhibitor belzutifan (MK-6482, previously called PT2977), administered orally at a dose of 120 mg daily, in patients with renal cell carcinoma associated with VHL disease. The primary end point was objective response (complete or partial response) as measured according to the Response Evaluation Criteria in Solid Tumors, version 1.1, by an independent central radiology review committee. We also assessed responses to belzutifan in patients with non-renal cell carcinoma neoplasms and the safety of belzutifan. After a median follow-up of 21.8 months (range, 20.2 to 30.1), the percentage of patients with renal cell carcinoma who had an objective response was 49% (95% confidence interval, 36 to 62). Responses were also observed in patients with pancreatic lesions (47 of 61 patients [77%]) and central nervous system hemangioblastomas (15 of 50 patients [30%]). Among the 16 eyes that could be evaluated in 12 patients with retinal hemangioblastomas at baseline, all (100%) were graded as showing improvement. The most common adverse events were anemia (in 90% of the patients) and fatigue (in 66%). Seven patients discontinued treatment: four patients voluntarily discontinued, one discontinued owing to a treatment-related adverse event (grade 1 dizziness), one discontinued because of disease progression as assessed by the investigator, and one patient died (of acute toxic effects of fentanyl). Belzutifan was associated with predominantly grade 1 and 2 adverse events and showed activity in patients with renal cell carcinomas and non-renal cell carcinoma neoplasms associated with VHL disease. (Funded by Merck Sharp and Dohme and others; MK-6482-004 ClinicalTrials.gov number, NCT03401788.).

Sections du résumé

BACKGROUND
Patients with von Hippel-Lindau (VHL) disease have a high incidence of renal cell carcinoma owing to
METHODS
In this phase 2, open-label, single-group trial, we investigated the efficacy and safety of the HIF-2α inhibitor belzutifan (MK-6482, previously called PT2977), administered orally at a dose of 120 mg daily, in patients with renal cell carcinoma associated with VHL disease. The primary end point was objective response (complete or partial response) as measured according to the Response Evaluation Criteria in Solid Tumors, version 1.1, by an independent central radiology review committee. We also assessed responses to belzutifan in patients with non-renal cell carcinoma neoplasms and the safety of belzutifan.
RESULTS
After a median follow-up of 21.8 months (range, 20.2 to 30.1), the percentage of patients with renal cell carcinoma who had an objective response was 49% (95% confidence interval, 36 to 62). Responses were also observed in patients with pancreatic lesions (47 of 61 patients [77%]) and central nervous system hemangioblastomas (15 of 50 patients [30%]). Among the 16 eyes that could be evaluated in 12 patients with retinal hemangioblastomas at baseline, all (100%) were graded as showing improvement. The most common adverse events were anemia (in 90% of the patients) and fatigue (in 66%). Seven patients discontinued treatment: four patients voluntarily discontinued, one discontinued owing to a treatment-related adverse event (grade 1 dizziness), one discontinued because of disease progression as assessed by the investigator, and one patient died (of acute toxic effects of fentanyl).
CONCLUSIONS
Belzutifan was associated with predominantly grade 1 and 2 adverse events and showed activity in patients with renal cell carcinomas and non-renal cell carcinoma neoplasms associated with VHL disease. (Funded by Merck Sharp and Dohme and others; MK-6482-004 ClinicalTrials.gov number, NCT03401788.).

Identifiants

DOI: 10.1056/NEJMoa2103425 PMID: 34818478 PMC: PMC9275515
pubmed: 34818478
doi: 10.1056/NEJMoa2103425
pmc: PMC9275515
mid: NIHMS1816481
doi:

Substances chimiques

Antineoplastic Agents 0
Basic Helix-Loop-Helix Transcription Factors 0
Indenes 0
belzutifan 7K28NB895L

Banques de données

ClinicalTrials.gov
['NCT03401788']

Types de publication

Clinical Trial, Phase II Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2036-2046

Subventions

Organisme : Medical Research Council
ID : MR/T024097/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U01 CA236489
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC011920
Pays : United States

Investigateurs

Eric Jonasch (E)
Amado J Zurita-Saavedra (AJ)
Amishi Shah (A)
Jianjun Gao (J)
John C Araujo (JC)
Matthew T Campbell (MT)
Nizar Tannir (N)
Sangeeta Goswami (S)
Zita Lim (Z)
Irene Cotton (I)
Oanh Pham (O)
Leah Shaw (L)
Kimryn Rathmell (K)
Kathryn Eby Beckerman (KE)
Kristin Kathleen Ancell (KK)
Deborah E Wallace (DE)
Ramaprasad Srinivasan (R)
Deborah Kay Hawkins (DK)
Nancy B Davis (NB)
Elizabeth Kaiser (E)
Kerry Schaffer (K)
W Marston Linehan (WM)
Prashant Chittiboina (P)
Kareem Zaghloul (K)
Julia Friend (J)
Peter Choyke (P)
Emily Chew (E)
Henry Wiley (H)
Jason Elinoff (J)
Mark Ball (M)
Vladimir Valera Romero (VV)
Donald P Bottaro (DP)
Cathy Vocke (C)
Erin Purcell (E)
Munjid Al Harthy (M)
Othon Iliopoulos (O)
Paul Leger (P)
Lisa Mac (L)
Carol Gurski (C)
Richard Lee (R)
Denise A Markt (DA)
Erika Meneely (E)
Dror Michaelson (D)
Kara Olivier (K)
Philip Saylor (P)
Matthew Smith (M)
Benjamin Maughan (B)
Neeraj Agarwal (N)
Tenzin Phunrab (T)
Samantha Greenberg (S)
Sumati Gupta (S)
Jared Thorley (J)
Julia Batten (J)
Will Lowrance (W)
Brock O'Neil (B)
Christopher Dechet (C)
Tobias Else (T)
Ajjai Alva (A)
Hakan Demirci (H)
Khaled Hafez (K)
Jenae Osborne (J)
Shane Quinonez (S)
Elena Stoffel (E)
Jodi Maranchie (J)
Ronald Hrebinko (R)
Benjamin Davies (B)
Bruce Jacobs (B)
Kayla Bishop (K)
Vivek Narayan (V)
David Vaughn (D)
Ronac Mamtani (R)
Naomi Balzer-Haas (N)
Katherine Nathanson (K)
Samuel Takvorian (S)
Mindy Dahan (M)
Jennifer Jones (J)
Joanna Ciconte (J)
Sarah Welsh (S)
Eamon Maher (E)
Tim Eisen (T)
Mary Denholm (M)
Kate Fife (K)
Athena Matakidou (A)
Frede Donskov (F)
Ane Iversen (A)
Mads Agerbaek (M)
Stephane Oudard (S)
Constance Thibault (C)
Yann-Alexandre Vano (YA)
Jacques Medioni (J)
Stephane Richard (S)

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 Massachusetts Medical Society.

Références

Nat Med. 2021 May;27(5):802-805
pubmed: 33888901
J Med Genet. 2017 Jan;54(1):11-18
pubmed: 27539272
Eur J Hum Genet. 2011 Jun;19(6):617-23
pubmed: 21386872
Curr Pharm Des. 2009;15(33):3895-903
pubmed: 19671042
Front Oncol. 2018 Jun 08;8:214
pubmed: 29938199
Nature. 2016 Nov 3;539(7627):107-111
pubmed: 27595393
Blood. 2005 Apr 15;105(8):3133-40
pubmed: 15626745
Clin Cancer Res. 2020 Feb 15;26(4):793-803
pubmed: 31727677
Nat Med. 2020 Oct;26(10):1519-1530
pubmed: 33020645
Lancet Oncol. 2018 Oct;19(10):1351-1359
pubmed: 30236511
Eur J Hum Genet. 2017 Feb;25(3):301-307
pubmed: 27966541
Oncotarget. 2016 Dec 20;7(51):85306-85317
pubmed: 27852035
J Clin Oncol. 2018 Mar 20;36(9):867-874
pubmed: 29257710
Nature. 2016 Nov 3;539(7627):112-117
pubmed: 27595394
J Clin Invest. 2007 Apr;117(4):1068-77
pubmed: 17404621
Ann Oncol. 2011 Dec;22(12):2661-2666
pubmed: 22105611
Mayo Clin Proc. 2000 Mar;75(3):265-72
pubmed: 10725953
Oncotarget. 2018 May 4;9(34):23390-23395
pubmed: 29805741
Front Pediatr. 2018 Feb 09;6:16
pubmed: 29479523
Oncol Res Treat. 2014;37(12):761-71
pubmed: 25531723
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:379-403
pubmed: 30625281

Auteurs

Eric Jonasch (E)

From the University of Texas M.D. Anderson Cancer Center, Houston (E.J.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (O.I.); Vanderbilt University Medical Center, Nashville (W.K.R.); University of Pennsylvania, Philadelphia (V.K.N.); the University of Utah, Salt Lake City (B.L.M.); Hôpital Européen Georges-Pompidou, University of Paris, Paris (S.O.); the University of Michigan, Ann Arbor (T.E.); the University of Pittsburgh, Pittsburgh (J.K.M.); Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (S.J.W.); Merck, Kenilworth, NJ (S.T., E.K.P., R.F.P.); and the Center for Cancer Research, National Cancer Institute, Bethesda, MD (W.M.L., R.S.).

Frede Donskov (F)

From the University of Texas M.D. Anderson Cancer Center, Houston (E.J.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (O.I.); Vanderbilt University Medical Center, Nashville (W.K.R.); University of Pennsylvania, Philadelphia (V.K.N.); the University of Utah, Salt Lake City (B.L.M.); Hôpital Européen Georges-Pompidou, University of Paris, Paris (S.O.); the University of Michigan, Ann Arbor (T.E.); the University of Pittsburgh, Pittsburgh (J.K.M.); Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (S.J.W.); Merck, Kenilworth, NJ (S.T., E.K.P., R.F.P.); and the Center for Cancer Research, National Cancer Institute, Bethesda, MD (W.M.L., R.S.).

Othon Iliopoulos (O)

From the University of Texas M.D. Anderson Cancer Center, Houston (E.J.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (O.I.); Vanderbilt University Medical Center, Nashville (W.K.R.); University of Pennsylvania, Philadelphia (V.K.N.); the University of Utah, Salt Lake City (B.L.M.); Hôpital Européen Georges-Pompidou, University of Paris, Paris (S.O.); the University of Michigan, Ann Arbor (T.E.); the University of Pittsburgh, Pittsburgh (J.K.M.); Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (S.J.W.); Merck, Kenilworth, NJ (S.T., E.K.P., R.F.P.); and the Center for Cancer Research, National Cancer Institute, Bethesda, MD (W.M.L., R.S.).

W Kimryn Rathmell (WK)

From the University of Texas M.D. Anderson Cancer Center, Houston (E.J.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (O.I.); Vanderbilt University Medical Center, Nashville (W.K.R.); University of Pennsylvania, Philadelphia (V.K.N.); the University of Utah, Salt Lake City (B.L.M.); Hôpital Européen Georges-Pompidou, University of Paris, Paris (S.O.); the University of Michigan, Ann Arbor (T.E.); the University of Pittsburgh, Pittsburgh (J.K.M.); Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (S.J.W.); Merck, Kenilworth, NJ (S.T., E.K.P., R.F.P.); and the Center for Cancer Research, National Cancer Institute, Bethesda, MD (W.M.L., R.S.).

Vivek K Narayan (VK)

From the University of Texas M.D. Anderson Cancer Center, Houston (E.J.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (O.I.); Vanderbilt University Medical Center, Nashville (W.K.R.); University of Pennsylvania, Philadelphia (V.K.N.); the University of Utah, Salt Lake City (B.L.M.); Hôpital Européen Georges-Pompidou, University of Paris, Paris (S.O.); the University of Michigan, Ann Arbor (T.E.); the University of Pittsburgh, Pittsburgh (J.K.M.); Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (S.J.W.); Merck, Kenilworth, NJ (S.T., E.K.P., R.F.P.); and the Center for Cancer Research, National Cancer Institute, Bethesda, MD (W.M.L., R.S.).

Benjamin L Maughan (BL)

From the University of Texas M.D. Anderson Cancer Center, Houston (E.J.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (O.I.); Vanderbilt University Medical Center, Nashville (W.K.R.); University of Pennsylvania, Philadelphia (V.K.N.); the University of Utah, Salt Lake City (B.L.M.); Hôpital Européen Georges-Pompidou, University of Paris, Paris (S.O.); the University of Michigan, Ann Arbor (T.E.); the University of Pittsburgh, Pittsburgh (J.K.M.); Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (S.J.W.); Merck, Kenilworth, NJ (S.T., E.K.P., R.F.P.); and the Center for Cancer Research, National Cancer Institute, Bethesda, MD (W.M.L., R.S.).

Stephane Oudard (S)

From the University of Texas M.D. Anderson Cancer Center, Houston (E.J.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (O.I.); Vanderbilt University Medical Center, Nashville (W.K.R.); University of Pennsylvania, Philadelphia (V.K.N.); the University of Utah, Salt Lake City (B.L.M.); Hôpital Européen Georges-Pompidou, University of Paris, Paris (S.O.); the University of Michigan, Ann Arbor (T.E.); the University of Pittsburgh, Pittsburgh (J.K.M.); Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (S.J.W.); Merck, Kenilworth, NJ (S.T., E.K.P., R.F.P.); and the Center for Cancer Research, National Cancer Institute, Bethesda, MD (W.M.L., R.S.).

Tobias Else (T)

From the University of Texas M.D. Anderson Cancer Center, Houston (E.J.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (O.I.); Vanderbilt University Medical Center, Nashville (W.K.R.); University of Pennsylvania, Philadelphia (V.K.N.); the University of Utah, Salt Lake City (B.L.M.); Hôpital Européen Georges-Pompidou, University of Paris, Paris (S.O.); the University of Michigan, Ann Arbor (T.E.); the University of Pittsburgh, Pittsburgh (J.K.M.); Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (S.J.W.); Merck, Kenilworth, NJ (S.T., E.K.P., R.F.P.); and the Center for Cancer Research, National Cancer Institute, Bethesda, MD (W.M.L., R.S.).

Jodi K Maranchie (JK)

From the University of Texas M.D. Anderson Cancer Center, Houston (E.J.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (O.I.); Vanderbilt University Medical Center, Nashville (W.K.R.); University of Pennsylvania, Philadelphia (V.K.N.); the University of Utah, Salt Lake City (B.L.M.); Hôpital Européen Georges-Pompidou, University of Paris, Paris (S.O.); the University of Michigan, Ann Arbor (T.E.); the University of Pittsburgh, Pittsburgh (J.K.M.); Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (S.J.W.); Merck, Kenilworth, NJ (S.T., E.K.P., R.F.P.); and the Center for Cancer Research, National Cancer Institute, Bethesda, MD (W.M.L., R.S.).

Sarah J Welsh (SJ)

From the University of Texas M.D. Anderson Cancer Center, Houston (E.J.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (O.I.); Vanderbilt University Medical Center, Nashville (W.K.R.); University of Pennsylvania, Philadelphia (V.K.N.); the University of Utah, Salt Lake City (B.L.M.); Hôpital Européen Georges-Pompidou, University of Paris, Paris (S.O.); the University of Michigan, Ann Arbor (T.E.); the University of Pittsburgh, Pittsburgh (J.K.M.); Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (S.J.W.); Merck, Kenilworth, NJ (S.T., E.K.P., R.F.P.); and the Center for Cancer Research, National Cancer Institute, Bethesda, MD (W.M.L., R.S.).

Sanjay Thamake (S)

From the University of Texas M.D. Anderson Cancer Center, Houston (E.J.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (O.I.); Vanderbilt University Medical Center, Nashville (W.K.R.); University of Pennsylvania, Philadelphia (V.K.N.); the University of Utah, Salt Lake City (B.L.M.); Hôpital Européen Georges-Pompidou, University of Paris, Paris (S.O.); the University of Michigan, Ann Arbor (T.E.); the University of Pittsburgh, Pittsburgh (J.K.M.); Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (S.J.W.); Merck, Kenilworth, NJ (S.T., E.K.P., R.F.P.); and the Center for Cancer Research, National Cancer Institute, Bethesda, MD (W.M.L., R.S.).

Eric K Park (EK)

From the University of Texas M.D. Anderson Cancer Center, Houston (E.J.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (O.I.); Vanderbilt University Medical Center, Nashville (W.K.R.); University of Pennsylvania, Philadelphia (V.K.N.); the University of Utah, Salt Lake City (B.L.M.); Hôpital Européen Georges-Pompidou, University of Paris, Paris (S.O.); the University of Michigan, Ann Arbor (T.E.); the University of Pittsburgh, Pittsburgh (J.K.M.); Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (S.J.W.); Merck, Kenilworth, NJ (S.T., E.K.P., R.F.P.); and the Center for Cancer Research, National Cancer Institute, Bethesda, MD (W.M.L., R.S.).

Rodolfo F Perini (RF)

From the University of Texas M.D. Anderson Cancer Center, Houston (E.J.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (O.I.); Vanderbilt University Medical Center, Nashville (W.K.R.); University of Pennsylvania, Philadelphia (V.K.N.); the University of Utah, Salt Lake City (B.L.M.); Hôpital Européen Georges-Pompidou, University of Paris, Paris (S.O.); the University of Michigan, Ann Arbor (T.E.); the University of Pittsburgh, Pittsburgh (J.K.M.); Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (S.J.W.); Merck, Kenilworth, NJ (S.T., E.K.P., R.F.P.); and the Center for Cancer Research, National Cancer Institute, Bethesda, MD (W.M.L., R.S.).

W Marston Linehan (WM)

From the University of Texas M.D. Anderson Cancer Center, Houston (E.J.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (O.I.); Vanderbilt University Medical Center, Nashville (W.K.R.); University of Pennsylvania, Philadelphia (V.K.N.); the University of Utah, Salt Lake City (B.L.M.); Hôpital Européen Georges-Pompidou, University of Paris, Paris (S.O.); the University of Michigan, Ann Arbor (T.E.); the University of Pittsburgh, Pittsburgh (J.K.M.); Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (S.J.W.); Merck, Kenilworth, NJ (S.T., E.K.P., R.F.P.); and the Center for Cancer Research, National Cancer Institute, Bethesda, MD (W.M.L., R.S.).

Ramaprasad Srinivasan (R)

From the University of Texas M.D. Anderson Cancer Center, Houston (E.J.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (O.I.); Vanderbilt University Medical Center, Nashville (W.K.R.); University of Pennsylvania, Philadelphia (V.K.N.); the University of Utah, Salt Lake City (B.L.M.); Hôpital Européen Georges-Pompidou, University of Paris, Paris (S.O.); the University of Michigan, Ann Arbor (T.E.); the University of Pittsburgh, Pittsburgh (J.K.M.); Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (S.J.W.); Merck, Kenilworth, NJ (S.T., E.K.P., R.F.P.); and the Center for Cancer Research, National Cancer Institute, Bethesda, MD (W.M.L., R.S.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Facteurs épidémiologiques › Facteurs âges › Âge de début › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › Hémopathies et maladies lymphatiques › Hémopathies › Anémie › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription à motif basique hélice-boucle-hélice › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › Néphrocarcinome › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Fatigue › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu vasculaire › Hémangiome › Hémangiome capillaire › Hémangioblastome › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › Composés polycycliques › Hydrocarbures aromatiques polycycliques › Indènes › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › Tumeurs › Tumeurs primitives multiples › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroendocrines › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › Belzutifan for Renal Cell Carcinoma in von...
questionsmedicales.fr › Malformations et maladies congénitales, héréditaires et néonatales › Maladies génétiques congénitales › Ciliopathies › Maladie de von Hippel-Lindau › Belzutifan for Renal Cell Carcinoma in von...